항염증제 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, anti-inflammatory drugs market size in 2026 is estimated at USD 129.33 billion, growing from 2025 value of USD 120.37 billion with 2031 projections showing USD 185.25 billion, growing at 7.45% CAGR over 2026-2031.

This report Segments the Industry Into by Application (Arthritis, Chronic Obstructive Pulmonary Disease, and More. ), Drug Class (Anti-Inflammatory Biologics, Nsaids, and More), Route of Administration (Oral, Parenteral, and More), Sales Channel (Prescription, Over the Counter), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Anti-Inflammatory Drugs Market Trends and Insights

Escalating Prevalence of Obesity-Linked Osteoarthritis

Growing obesity and longevity are jointly raising osteoarthritis caseloads, stimulating the anti-inflammatory drugs market. Mechanical strain and low-grade systemic inflammation accelerate cartilage loss, driving sustained demand for safe analgesia. Observational studies indicate topical diclofenac gel yields symptom relief with 74.2% of users reporting no adverse events, a meaningful safety edge for obese patients with cardiovascular comorbidity. Payers endorse weight-neutral therapeutics and integrated metabolic-inflammation regimens, expanding formularies for topical NSAIDs and glucosamine combinations. Device-coupled drug delivery and single-visit depot corticosteroid injections further heighten adherence. Collectively, obesity-driven osteoarthritis provides a long-run volume anchor for the anti-inflammatory drugs market.

Biologics Pipeline Acceleration Through AI-Enabled Discovery

Generative algorithms shorten target identification, optimize binding affinity and de-risk lead candidates, enabling faster biologic entry. Insilico Medicine progressed ISM5411 for inflammatory bowel disease from in-silico concept to Phase 1 inside 30 months. Big Pharma now pairs internal libraries with AI platforms to refresh immunology portfolios, enhancing the anti-inflammatory drugs market with differentiated mechanisms. Companion diagnostics derived from genomics refine patient selection, bolstering trial success rates and payer acceptance. The virtuous cycle of data, modeling and clinical validation promises sustained biologics innovation through 2030. Regions with strong digital infrastructure, notably the United States, Germany and the United Kingdom, capture much of this activity, but strategic partnerships extend capacity into China and Singapore research hubs.

Cardiovascular Boxed-Warnings on COX-2 NSAIDs

Although the PRECISION trial positioned celecoxib as non-inferior to naproxen or ibuprofen for major adverse cardiac events, prescriber caution persists. FDA advisory committees considered but did not remove celecoxib warnings, sustaining perception hurdles Arthritis Foundation. Korean insurance data on ankylosing spondylitis indicated dose-dependent cardiovascular risk with adjusted hazard ratio of 1.12 for heart failure Annals of the Rheumatic Diseases. Clinicians therefore limit high-dose or long-term COX-2 NSAID use, especially in older or high-risk patients. The restraint caps systemic NSAID growth and shifts volume toward topical NSAIDs and biologics, marginally slowing the anti-inflammatory drugs market.

Other drivers and restraints analyzed in the detailed report include:

1. Prescription-to-OTC Switches for Topical NSAIDs
2. Wider Uptake of JAK Inhibitors After Unified Safety Labels
3. Biologic Price Erosion From Biosimilars in EU5

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Arthritis applications command 27.42% market share in 2025, reflecting the segment's established treatment protocols and large patient population requiring chronic management. However, tendonitis emerges as the fastest-growing application at 8.05% CAGR through 2031, driven by evolving treatment paradigms that emphasize early intervention and targeted anti-inflammatory approaches. Recent preclinical research demonstrates that both local and oral NSAIDs provide effective short-term relief for tendon overuse-related pain, with particular efficacy in acute shoulder tendonitis and bursitis. Multiple sclerosis and inflammatory bowel disease applications are experiencing robust growth as new targeted therapies expand treatment options, while COPD applications benefit from steroid-sparing regimens that reduce long-term complications.

The application landscape is being reshaped by precision medicine approaches that match specific inflammatory pathways to targeted interventions. Tendon-bone healing research emphasizes the critical role of inflammatory modulation, with emerging therapies focusing on macrophage polarization and cytokine regulation to optimize repair processes. Asthma applications are witnessing significant innovation with JAK inhibitors demonstrating efficacy across multiple inflammatory cascades, while other treatment categories benefit from combination approaches that address both acute symptoms and underlying disease progression. The shift toward application-specific biomarkers and companion diagnostics is enabling more precise treatment selection, particularly in complex conditions where multiple inflammatory pathways contribute to disease pathology.

Anti-inflammatory biologics maintain market leadership with 32.10% share in 2025 and drive growth at 8.12% CAGR through 2031, reflecting continued innovation in targeted immunomodulation and expanding indication approvals. The class benefits from AI-accelerated drug discovery, with generative platforms enabling more precise target identification and molecular optimization that reduces development timelines and improves success rates. Non-steroidal anti-inflammatory drugs remain essential for acute management, while corticosteroids face pressure from steroid-sparing alternatives that offer comparable efficacy with reduced adverse effect profiles. Immune-selective anti-inflammatory derivatives represent an emerging category that promises more precise inflammatory modulation with fewer systemic effects.

Recent regulatory approvals demonstrate the biologics segment's momentum, with upadacitinib receiving its eighth indication for giant cell arteritis and demonstrating 46.4% sustained remission rates compared to 29.0% for placebo. The segment is also benefiting from novel mechanisms of action, including TL1A inhibitors that are showing superior efficacy in inflammatory bowel disease, with Merck's PRA-023 achieving 49.1% remission rates in Crohn's disease patients. Other drug classes are evolving toward combination approaches and sustained-release formulations that improve patient compliance and therapeutic outcomes while reducing dosing frequency and systemic exposure.

Complete Report Scope:

• By Application
  • Arthritis
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Multiple Sclerosis
  • Inflammatory Bowel Disease (IBD)
  • Asthma
  • Tendonitis
  • Other Applications
• By Drug Class
  • Anti-Inflammatory Biologics
  • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Immune-selective Anti-inflammatory Derivatives (ImSAIDs)
  • Other Drug Classes
• By Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Inhalation
• By Sales Channel
  • Prescription
  • Over-the-Counter (OTC)
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 38.35% of global revenue in 2025, underpinned by advanced reimbursement, rapid uptake of novel agents and rigorous clinical research capacity. The United States approved JOURNAVX, the first non-opioid NaV1.8 blocker for acute pain, reinforcing therapeutic leadership. Biosimilar penetration, including adalimumab alternatives, aligns with payer cost-containment goals, slightly moderating net sales growth. Federal incentives to reshore key APIs and diversify sourcing address supply vulnerabilities exposed during 2024 logistics disruptions. Canada expands real-world evidence requirements, enhancing post-marketing surveillance and driving formulary refinement.

Asia-Pacific records the highest 8.2% CAGR through 2031. China's centralized procurement lowers biologic prices and accelerates hospital uptake, while domestic manufacturers scale TNF inhibitor biosimilars. India's Ayushman Bharat insurance scheme enlarges patient coverage and boosts retail OTC demand. Japan remains a bellwether for aging-related inflammatory disease, supporting steady biologic utilization. Southeast Asian markets invest in clinical trial infrastructure, attracting multinational sponsors. Collectively, rising income, urbanization and chronic disease prevalence fuel anti-inflammatory drugs market expansion in the region.

Europe holds meaningful share but faces intensified price erosion from biosimilars. Germany's early access pathways and digital therapeutics pilots demonstrate commitment to innovation, yet health technology assessments demand robust cost-effectiveness evidence. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) post-Brexit flexibility expedites approvals, balancing competition with patient access. The Middle East and Africa invest in tiered formulary systems and biosimilar adoption to widen therapy reach, while Latin America modernizes regulatory frameworks, encouraging multinationals to localize production. Those developments collectively sustain global momentum for the anti-inflammatory drugs market while highlighting regional nuances.

1. Abbvie
2. Amgen
3. AstraZeneca
4. Bayer
5. Boehringer Ingelheim
6. Bristol-Myers Squibb
7. Eli Lilly and Company
8. Roche
9. GlaxoSmithKline
10. Gilead Sciences
11. Johnson & Johnson
12. Merck
13. Novartis
14. Pfizer
15. Regeneron
16. Sanofi
17. Teva Pharmaceutical Industries
18. UCB
19. Viatris
20. Zydus Lifesciences

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating Prevalence of Obesity-linked Osteoarthritis
  • 4.2.2 Biologics pipeline Acceleration due to AI-enabled Target Discovery
  • 4.2.3 Expansion of OTC Topical NSAID Switches in Europe & U.S.
  • 4.2.4 Uptake of JAK-inhibitors after Safety-label Harmonisation
  • 4.2.5 Growing Demand for Once-weekly Depot Corticosteroid Injectables
  • 4.2.6 Hospital Antimicrobial-stewardship Programs Favouring Steroid-sparing Regimens
• 4.3 Market Restraints
  • 4.3.1 Cardiovascular Boxed-warnings on COX-2 NSAIDs
  • 4.3.2 Biologic Price Erosion from Biosimilars in EU5
  • 4.3.3 Rising Litigation over Proton-pump-inhibitor Co-prescriptions
  • 4.3.4 Supply-chain Vulnerability of API Precursors Sourced from China
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Application
  • 5.1.1 Arthritis
  • 5.1.2 Chronic Obstructive Pulmonary Disease (COPD)
  • 5.1.3 Multiple Sclerosis
  • 5.1.4 Inflammatory Bowel Disease (IBD)
  • 5.1.5 Asthma
  • 5.1.6 Tendonitis
  • 5.1.7 Other Applications
• 5.2 By Drug Class
  • 5.2.1 Anti-Inflammatory Biologics
  • 5.2.2 Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 5.2.3 Corticosteroids
  • 5.2.4 Immune-selective Anti-inflammatory Derivatives (ImSAIDs)
  • 5.2.5 Other Drug Classes
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Parenteral
  • 5.3.3 Topical
  • 5.3.4 Inhalation
• 5.4 By Sales Channel
  • 5.4.1 Prescription
  • 5.4.2 Over-the-Counter (OTC)
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 AbbVie
  • 6.3.2 Amgen
  • 6.3.3 AstraZeneca
  • 6.3.4 Bayer
  • 6.3.5 Boehringer Ingelheim
  • 6.3.6 Bristol-Myers Squibb
  • 6.3.7 Eli Lilly
  • 6.3.8 F. Hoffmann-La Roche
  • 6.3.9 GSK
  • 6.3.10 Gilead Sciences
  • 6.3.11 Johnson & Johnson
  • 6.3.12 Merck & Co
  • 6.3.13 Novartis
  • 6.3.14 Pfizer
  • 6.3.15 Regeneron
  • 6.3.16 Sanofi
  • 6.3.17 Teva Pharmaceutical
  • 6.3.18 UCB Pharma
  • 6.3.19 Viatris
  • 6.3.20 Zydus Lifesciences

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment